Merck (MRK) Outperforms Industry, What's In Store For 2022?
March 07, 2022 at 09:45 AM EST
Merck boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales.
